2021年2月1日

蓝莓疗法有限想宣布,它已经完成了£3.6扩展先前成功的系列B筹款£10.8 m。这项投资是来自日本投资者,日本医学孵化器(MIJ)和一个私人财团的奥马尔·易卜拉欣博士领导的委员会认证的皮肤科医生,CT。蓝莓疗法是一种dermatology-focused药物发现和开发公司致力于开发创新的纳米药物难以治疗疾病的皮肤和指甲,在二期开发领先候选人。筹资在一定程度上是为了应对COVID-19大流行,它直接影响了全球临床试验,但主要是因为一系列的临床前成功在2020年期间,扩大了公司的药物组合。蓝莓系列疗法将使用B扩展收益继续开发计划署BB2603治疗甲真菌病,和额外的资金将被用于其他项目,包括脚癣,哪里有鼓舞人心的疗效和安全性数据和潜在市场的有效途径。BB2603蓝莓疗法领导开发的候选药物;在完成2018年I / II期研究,这是在二期临床的发展。利用纳米技术,BB2603旨在极大地提高交付的目标下的真菌感染的指甲和皮肤的上层内。甲癣,BB2603旨在实现等价的疗效和治疗时间,但低于批准的几千倍的剂量口服terbinafine,从而避免了系统性副作用和患者口服的监控需求。额外的资金支持完成第二阶段研究研究中,前三期临床发展的美国和欧盟对甲真菌病的治疗。 Medical Incubator Japan is an independent healthcare-focused venture capital company aimed at investing in early-stage life sciences companies across a broad range of innovations including drug discovery, digital health and medical devices. Its second fund launched in the summer of 2020, focusing on investments both in Japan and overseas. Through its partnership with Bamburgh Capital, MIJ is particularly focused on identifying investment opportunities in the UK, where MIJ is attracted by the compelling opportunities to invest in innovative companies opening up world-class science and supported by collaborative, informed and influential ecosystems. Japan is the third largest healthcare market in the world and MIJ will be able to help Blueberry Therapeutics access this important market. Mr. Jun Katsura, President and Co-CEO of MIJ, commented: “We are very pleased to be a shareholder in Blueberry Therapeutics and to be able to support the management team in its quest to deliver high value innovative medicines for patients suffering from a range of dermatological disorders, and we look forward to collaborating in the development of the Company’s products.” Dr Omar Ibrahimi, Founding Medical Director at the Connecticut Skin Institute commented: “The team and I were impressed with the Blueberry approach and felt that the Blueberry technology was compelling enough to invest our own money in developing it further. BB2603 addresses a clinical problem that we have struggled to treat effectively for decades.” Dr. John Ridden, Chief Executive Officer of Blueberry Therapeutics said: “I am delighted to have MIJ, and Omar and syndicate as investors and I very much look forward to working with them on our plans for Japan and the US. This funding extension not only enables us to progress our main onychomycosis programme to the next stages of development, but it also enhances our relationships in the critically important Japanese and US markets” News Source: